Abbott Laboratories' cholesterol-lowering treatment Simcor significantly reduced "bad" LDL cholesterol and improved "good" HDL cholesterol compared to simvastatin during its Phase III clinical trial. The company hopes to get regulatory approval for Simcor, a combination of simvastatin and another drug from Abbott, during the first quarter of 2008.

Full Story:

Related Summaries